Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aumolertinib maintenance after postoperative adjuvant chemoradiotherapy in EGFR-mutant stage III N2 NSCLC
ChiCTR2200057150Phase 4Not yet recruiting
- Sponsor
- Guizhou Provincial People's Hospital
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of almonertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Guizhou Provincial People's Hospital. Primary endpoint: Disease-free survival at 2 years. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200057150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057150.